| [1] |
Ravegnini G, Sammarini G, Nannini M, et al. Gastrointestinal stromal tumors (GIST): facing cell death between autophagy and apoptosis[J]. Autophagy, 2017, 13(3): 452-463.
|
| [2] |
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors[J]. Science, 1998, 279(5350): 577-580.
|
| [3] |
Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors[J]. Science, 2003, 299(5607): 708-710.
|
| [4] |
Nannini M, Biasco G, Astolfi A, et al. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST)[J]. J Med Genet, 2013, 50(10): 653-661.
|
| [5] |
Cioffi A, Maki RG. GI stromal tumors: 15 years of lessons from a rare cancer[J]. J Clin Oncol, 2015, 33(16): 1849-1854.
|
| [6] |
Li J, Ye Y, Wang J, et al. Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor[J]. Chin J Cancer Res, 2017, 29(4): 281-293.
|
| [7] |
Bevers TB, Helvie M, Bonaccio E, et al. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2018, 16(11): 1362-1389.
|
| [8] |
Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT[J]. J Clin Oncol, 2008, 26(4): 620-625.
|
| [9] |
Zhang Q, Xu J, Qian Y, et al. Association of imatinib plasma concentration and single nucleotide polymorphisms with adverse drug reactions in patients with gastrointestinal stromal tumors[J]. Mol Cancer Ther, 2018, 17(12): 2780-2787.
|
| [10] |
Takahashi T, Elzawahry A, Mimaki S, et al. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors[J]. Genes Chromosomes Cancer, 2017, 56(4): 303-313.
|
| [11] |
Pierotti MA, Tamborini E, Negri T, et al. Targeted therapy in GIST: in silico modeling for prediction of resistance[J]. Nat Rev Clin Oncol, 2011, 8(3): 161-170.
|
| [12] |
Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology[J]. Nat Rev Cancer, 2011, 11(12): 865-878.
|
| [13] |
Ravegnini G, Urbini M, Simeon V, et al. An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor[J]. Pharmacogenomics J, 2019, 19(4): 390-400.
|
| [14] |
Widmer N, Rumpold H, Untergasser G, et al. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels[J]. Leukemia, 2007, 21(7): 1561-1562; author reply 1562-1564.
|
| [15] |
徐皓，马利林，徐为, 等. 胃肠间质瘤患者服药前后监测伊马替尼血浆浓度意义的中国多中心研究[J]. 中华胃肠外科杂志, 2016, 19(11): 1271-1276.
|
| [16] |
Berglund E, Ubhayasekera SJ, Karlsson F, et al. Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells[J]. Anticancer Drugs, 2014, 25(4): 415-422.
|
| [17] |
Zhang Q, Li Z, Xu K, et al. Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor[J]. Scand J Gastroenterol, 2019, 54(2): 220-226.
|
| [18] |
Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer[J]. Nat Rev Cancer, 2018, 18(7): 452-464.
|